$PLRZ

Polyrizon Ltd. (PLRZ) has finished enrolling 120 patients in its U.S. clinical trial for NASARIX, a nasal hydrogel for allergic rhinitis, comparing it to saline control across five sites. This marks an early operational milestone.

Polyrizon Ltd. (Nasdaq: PLRZ) filed a new U.S. patent application (No. 19/823,285) for its mucoadhesive technology, expanding its IP portfolio for intranasal drug delivery. The company aims to strengthen its patent protection for nasal drug delivery applications, a key part of its strategy. Polyrizon's technology is designed for prolonged interaction with mucosal surfaces, potentially offering new approaches to local and systemic intranasal delivery.

Polyrizon Ltd. (PLRZ) completed contracting with U.S. clinical sites for its NASARIX Allergy Blocker (PL-14) trial, advancing into first-in-human study execution. The trial will evaluate efficacy, safety, and tolerability in 120 patients with seasonal allergic rhinitis. PLRZ stock traded between $2.88 and $18.20 over the past year, closing at $14.36 on Tuesday.

Polyrizon Ltd. (NASDAQ: PLRZ) said its NASARIX™ Allergy Blocker intranasal hydrogel nasal spray passed biocompatibility and biological safety tests, meeting predetermined acceptance criteria. The program covered endpoints including cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, with long-term systemic toxicity assessed via ISO 10993-17 risk review.

Polyrizon Ltd. (Nasdaq: PLRZ) said its NASARIX™ intranasal allergy-blocker biocompatibility program completed successfully, with required biological safety tests meeting preset acceptance criteria. The program covered cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, plus long-term systemic toxicity risk assessment under ISO 10993. The company said results support advancement toward first-in-human clinical trials.

Polyrizon Ltd. (NASDAQ:PLRZ) shares rose about 10% after the company reported successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. Polyrizon said required biological safety endpoints met predetermined acceptance criteria under ISO 10993 and related FDA/EU guidance, supporting progress toward clinical and regulatory steps.

uniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.

Polyrizon Ltd. director Carmel Liron reported an open-market sale of 100 Ordinary Shares at $11.00 per share on March 30, 2026. Following this transaction, Liron directly holds 4,069 ordinary shares, which include 1,463 unrestricted shares and 2,606 restricted ordinary shares that vest quarterly conditional on continued service. The filing also clarifies that no derivative securities were involved in this transaction.

Polyrizon Ltd.'s Chief Technology Officer, Tidhar Turgeman, has sold 2,917 Ordinary Shares at $10.90 per share in an open-market transaction, as reported in a recent Form 4 filing. Following this sale, Turgeman directly holds 17,518 Ordinary Shares, which include 18 restricted shares vesting monthly and 17,500 restricted shares vesting quarterly, contingent on his continued employment. The transaction is categorized as a neutral filing impact with a negative sentiment, reflecting a routine insider sale rather than a grant or option exercise.

Polyrizon (NASDAQ:PLRZ) is an unprofitable biotech company currently burning cash, with a cash runway of about 2.5 years based on its US$11m cash reserves and US$4.5m annual burn rate. While its runway is considered reasonable, its cash burn increased by 295% in the last year, which could lead to significant shareholder dilution if it needs to raise more capital. Despite the high burn rate, the company's cash runway provides some comfort to investors.